Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Galectin Therapeutics (GALT) stock drops 25% as NAVIGATE trial for belapectin in liver disorder MASH fails to meet main goal.

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 85.37% +13.41, ...

Galectin Therapeutics Inc. Common Stock (GALT) stock saw a decline, ending the day at $1.04 which represents a decrease of $-0.96 or -48.00% from the prior close of $2. The stock opened at $1.18 and ...

Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic ...

Galectin Therapeutics' NAVIGATE trial shows belapectin reduces varices in MASH cirrhosis, but falls short of statistical targets; full data due in early 2025.

Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. The stock lost more than half its value, falling to about 91 cents ...

Galectin Therapeutics (NASDAQ:GALT) lost ~25% in the premarket on Friday after its NAVIGATE clinical trial for lead candidate belapectin failed to reach the main goal in patients with liver ...

The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...

Galectin Therapeutics Inc. (NASDAQ: GALT) revealed the top-line results of its NAVIGATE clinical trial in a recent press release. The trial evaluated belapectin in patients with cirrhotic portal ...